Syncom Formulations (SYNCOMF) | Stock Overview & Key Data
Syncom Formulations Performance Comparison
Stock Range
Today's Range
Low: ₹17.60
High: ₹17.95
on August 13, 2025
52 Week Range
Low: ₹14.10
High: ₹27.90
on March 3, 2025
on September 10, 2024
All-Time High: ₹27.90 on September 9, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR17.2B
EPS
0.57
P/E Ratio (TTM)
32.05
Forward P/E
N/A
P/B Ratio
5.90
PEG Ratio
0.29
Div. Yield
N/A
ROE
15.69%
Beta
1.322
Debt to Equity
1.34
Financial Highlights
Profitability
Gross Margin
32.58%
Operating Margin
11.06%
Profit Margin
10.63%
Returns and Earnings
Return on Assets (TTM)
7.48%
Return on Equity (TTM)
15.69%
EBITDA
INR715.7M
Net Income (TTM)
INR494.3M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR4.95
Quarterly Revenue Growth (YoY)
99.60%
Quarterly Earnings Growth (YoY)
139.00%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Syncom Formulations SYNCOMF | 17.19B Small-cap | -2.64% | -6.94% | 7.66% | -1.99% | -14.99% | 16.37% | 122.96% | 122.96% |
| Sun Pharmaceutical SUNPHARMA | 3.81T Large-cap | -0.61% | -3.59% | -3.80% | -4.23% | -14.17% | -7.71% | 78.44% | 202.13% |
| Divi's Laboratories DIVISLAB | 1.59T Large-cap | -6.99% | -12.06% | 0.32% | -0.15% | -1.84% | 28.64% | 61.27% | 83.57% |
| Sun Pharma Advanced SPARC | 46.41B Small-cap | -2.63% | -11.98% | -4.53% | -3.07% | -29.29% | -33.23% | -41.02% | -21.77% |
| Aarti Drugs AARTIDRUGS | 44.67B Small-cap | 1.65% | 1.81% | 14.25% | 24.49% | 7.45% | -1.48% | 9.59% | -37.52% |
| Sequent Scientific SEQUENT | 43.53B Small-cap | -2.62% | -6.11% | 2.95% | 14.81% | -5.65% | 23.40% | 60.75% | 35.04% |
Ownership & Short Interest
Insider Ownership
50.57%
Institutional Ownership
0.06%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
796K
Average 90-Day Volume
856K
Syncom Formulations Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Syncom Formulations would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SYNCOMF's 52-week high and low?
- In the last 52 weeks, Syncom Formulations reached a high of ₹27.90 (on September 10, 2024) and a low of ₹14.10 (on March 3, 2025).
- What is the market cap and P/E ratio for SYNCOMF?
- Curious about Syncom Formulations's size and valuation? Its market capitalization stands at 17.19B. When it comes to valuation, the P/E ratio (trailing twelve months) is 32.05, and the forward P/E (looking ahead) is N/A.
- Does SYNCOMF pay dividends? If so, what's the yield?
- As for dividends, Syncom Formulations isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Syncom Formulations's main competitors or similar companies to consider before investing?
When looking at Syncom Formulations, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.81T Healthcare Drug Manufacturers - Specialty & Generic -7.71% 78.44% Divi's Laboratories
DIVISLAB1.59T Healthcare Drug Manufacturers - Specialty & Generic 28.64% 61.27% Sun Pharma Advanced
SPARC46.41B Healthcare Drug Manufacturers - Specialty & Generic -33.23% -41.02% Aarti Drugs
AARTIDRUGS44.67B Healthcare Drug Manufacturers - Specialty & Generic -1.48% 9.59% Sequent Scientific
SEQUENT43.53B Healthcare Drug Manufacturers - Specialty & Generic 23.40% 60.75% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Syncom Formulations (India) Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Syncom Formulations's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 15.69%, the Debt to Equity ratio from the most recent quarter is 1.34, and its Gross Profit Margin stands at 32.58%.
- What is the recent revenue and earnings growth for SYNCOMF?
- Looking at Syncom Formulations's growth, its revenue over the trailing twelve months (TTM) was INR5B. Compared to the same quarter last year (YoY), quarterly revenue grew by 99.60%, and quarterly earnings saw a YoY growth of 139.00%.
- How much of SYNCOMF stock is held by insiders and institutions?
- Wondering who owns Syncom Formulations stock? Company insiders (like executives and directors) hold about 50.57% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.06%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.